The financials
Cencora by the numbers
Cencora (COR) reported revenue of $84.8B in Q3 2026 (quarter ended June 30, 2026), up 5.1% from the same quarter a year earlier. That came with a gross margin of 4.3% and net income of $764M (0.9% of revenue). For the full year FY2025, revenue was $321.3B (+9.3% year on year) and net income $1.55B. Its largest segment in 2026-Q1 was US Healthcare Solutions at $68.8B, 91% of the disclosed total, just ahead of International Healthcare Solutions at 8.7%.
| Income statement | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $84.8B | $80.7B | +5.1% |
| Gross profit | $3.61B | $2.91B | +24% |
| Operating income | $1.12B | $868M | +29% |
| Net income | $764M | $687M | +11% |
| Diluted EPS | $3.94 | $3.52 | +12% |
| Operating | Revenue | Share |
|---|---|---|
| US Healthcare Solutions | $68.8B | 91% |
| International Healthcare Solutions | $6.52B | 8.7% |
Business Segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q1 2026Total $75.28B (-9.0%)
International Healthcare Solutions grew +13% year on yearUS Healthcare Solutions +2.9% year on year
Segment Latestquarter on quarteryear on year
- US Healthcare Solutions$68.77B$68.77BQoQ -9.8%year on year +2.9%-9.8%+2.9%
- International Healthcare Solutions$6.52B$6.52BQoQ -0.22%year on year +13%-0.22%+13%